Table of Contents

Global Anti-Infective Drug Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate

1 Market Scope

• 1.1 Product Details and Introduction
  • 1.1.1 Antibiotics -Product Introduction and Major Manufacturers
  • 1.1.2 Antivirals -Product Introduction and Major Manufacturers
  • 1.1.3 Antifungals -Product Introduction and Major Manufacturers
  • 1.1.4 Others -Product Introduction and Major Manufacturers
• 1.2 Market Snapshot
  • 1.2.1 Major Companies Overview
  • 1.2.2 Market Concentration
  • 1.2.3 Six-Year Compound Annual Growth Rate (CAGR)

2 Global Anti-Infective Drug Market Assessment, by Segmentation

• 2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
• 2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
• 2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)

3 Regional Market Analysis

• 3.1 China Anti-Infective Drug Market
  • 3.1.1 Top Companies leading Anti-Infective Drug Development in China (2015-2020)
  • 3.1.2 Sales Value of Major Company in China Market (2015-2020)
  • 3.1.3 China Anti-Infective Drug Price (USD/Unit), by Type (2019-2020)
  • 3.1.4 Sales in China Market, by Type (2015-2026)
• 3.2 EU Anti-Infective Drug Market
  • 3.2.1 Top Companies leading Anti-Infective Drug Development in EU (2015-2020)
  • 3.2.2 Sales Value of Major Company in EU Market (2015-2020)
  • 3.2.3 EU Anti-Infective Drug Price (USD/Unit), by Type (2019-2020)
  • 3.2.4 Sales in EU Market, by Type (2015-2026)
• 3.3 USA Anti-Infective Drug Market
  • 3.3.1 Top Companies leading Anti-Infective Drug Development in USA (2015-2020)
  • 3.3.2 Sales Value of Major Company in USA Market (2015-2020)
  • 3.3.3 USA Anti-Infective Drug Price (USD/Unit), by Type (2019-2020)
  • 3.3.4 Sales in USA Market, by Type (2015-2026)
• 3.4 Japan Anti-Infective Drug Market
  • 3.4.1 Top Companies leading Anti-Infective Drug Development in Japan (2015-2020)
  • 3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
  • 3.4.3 Japan Anti-Infective Drug Price (USD/Unit), by Type (2019-2020)
  • 3.4.4 Sales in Japan Market, by Type (2015-2026)
• 3.5 India Anti-Infective Drug Market
  • 3.5.1 Top Companies leading Anti-Infective Drug Development in India (2015-2020)
  • 3.5.2 Sales Value of Major Company in India Market (2015-2020)
  • 3.5.3 India Anti-Infective Drug Price (USD/Unit), by Type (2019-2020)
  • 3.5.4 Sales in India Market, by Type (2015-2026)
• 3.6 Southeast Asia Anti-Infective Drug Market
  • 3.6.1 Top Companies leading Anti-Infective Drug Development in Southeast Asia (2015-2020)
  • 3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
  • 3.6.3 Southeast Asia Anti-Infective Drug Price (USD/Unit), by Type (2019-2020)
  • 3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
• 3.7 South America Anti-Infective Drug Market
  • 3.7.1 Top Companies leading Anti-Infective Drug Development in South America (2015-2020)
  • 3.7.2 Sales Value of Major Company in South America Market (2015-2020)
  • 3.7.3 South America Anti-Infective Drug Price (USD/Unit), by Type (2019-2020)
  • 3.7.4 Sales in South America Market, by Type (2015-2026)

4 Value Chain (Impact of COVID-19)

• 4.1 Anti-Infective Drug Value Chain Analysis
  • 4.1.1 Upstream
  • 4.1.2 Downstream
• 4.2 COVID-19 Impact on Anti-Infective Drug Industry
  • 4.2.1 Industrial Policy Issued Under the Epidemic Situation
• 4.3 Cost-Under the Epidemic Situation
  • 4.3.1 Cost of Raw Material
• 4.4 Channel Analysis
  • 4.4.1 Distribution Channel-Under the Epidemic Situation
  • 4.4.2 Distributors

5 Regional Market Forecast (2021-2026)

• 5.1 Global Anti-Infective Drug Sales and Growth Rate (2021-2026)
• 5.2 Global Anti-Infective Drug Sales Value and Growth Rate (2021-2026)

6 Anti-Infective Drug Competitive Analysis

• 6.1 Gilead Sciences
  • 6.1.1 Gilead Sciences Company Profiles
  • 6.1.2 Gilead Sciences Product Introduction
  • 6.1.3 Gilead Sciences Anti-Infective Drug Production, Revenue (2015-2020)
  • 6.1.4 SWOT Analysis
• 6.2 GlaxoSmithKline
  • 6.2.1 GlaxoSmithKline Company Profiles
  • 6.2.2 GlaxoSmithKline Product Introduction
  • 6.2.3 GlaxoSmithKline Anti-Infective Drug Production, Revenue (2015-2020)
  • 6.2.4 SWOT Analysis
• 6.3 Merck
  • 6.3.1 Merck Company Profiles
  • 6.3.2 Merck Product Introduction
  • 6.3.3 Merck Anti-Infective Drug Production, Revenue (2015-2020)
  • 6.3.4 SWOT Analysis
• 6.4 Teva Pharmaceutical Industries
  • 6.4.1 Teva Pharmaceutical Industries Company Profiles
  • 6.4.2 Teva Pharmaceutical Industries Product Introduction
  • 6.4.3 Teva Pharmaceutical Industries Anti-Infective Drug Production, Revenue (2015-2020)
  • 6.4.4 SWOT Analysis
• 6.5 Johnson & Johnson
  • 6.5.1 Johnson & Johnson Company Profiles
  • 6.5.2 Johnson & Johnson Product Introduction
  • 6.5.3 Johnson & Johnson Anti-Infective Drug Production, Revenue (2015-2020)
  • 6.5.4 SWOT Analysis
• 6.6 Boehringer Ingelheim
  • 6.6.1 Boehringer Ingelheim Company Profiles
  • 6.6.2 Boehringer Ingelheim Product Introduction
  • 6.6.3 Boehringer Ingelheim Anti-Infective Drug Production, Revenue (2015-2020)
  • 6.6.4 SWOT Analysis
• 6.7 Pfizer
  • 6.7.1 Pfizer Company Profiles
  • 6.7.2 Pfizer Product Introduction
  • 6.7.3 Pfizer Anti-Infective Drug Production, Revenue (2015-2020)
  • 6.7.4 SWOT Analysis
• 6.8 Mylan N.V.
  • 6.8.1 Mylan N.V. Company Profiles
  • 6.8.2 Mylan N.V. Product Introduction
  • 6.8.3 Mylan N.V. Anti-Infective Drug Production, Revenue (2015-2020)
  • 6.8.4 SWOT Analysis
• 6.9 Bristol-Myers Squibb
  • 6.9.1 Bristol-Myers Squibb Company Profiles
  • 6.9.2 Bristol-Myers Squibb Product Introduction
  • 6.9.3 Bristol-Myers Squibb Anti-Infective Drug Production, Revenue (2015-2020)
  • 6.9.4 SWOT Analysis
• 6.10 F. Hoffmann-La Roche
  • 6.10.1 F. Hoffmann-La Roche Company Profiles
  • 6.10.2 F. Hoffmann-La Roche Product Introduction
  • 6.10.3 F. Hoffmann-La Roche Anti-Infective Drug Production, Revenue (2015-2020)
  • 6.10.4 SWOT Analysis
• 6.11 Shanghai Pharmaceuticals

7 Conclusion

Summary

As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.

Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Anti-Infective Drug market in this environment.

In terms of revenue, this research report indicated that the global Anti-Infective Drug market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Anti-Infective Drug industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.

The Gilead Sciences aims at producing XX Anti-Infective Drug in 2020, with XX % production to take place in global market, GlaxoSmithKline accounts for a volume share of XX %.

Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Anti-Infective Drug Market by XYZResearch Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Anti-Infective Drug Market?
Gilead Sciences
GlaxoSmithKline
Merck
Teva Pharmaceutical Industries
Johnson & Johnson
Boehringer Ingelheim
Pfizer
Mylan N.V.
Bristol-Myers Squibb
F. Hoffmann-La Roche
Shanghai Pharmaceuticals
...
Major Type of Anti-Infective Drug Covered in XYZResearch report:
Antibiotics
Antivirals
Antifungals
Others
Application Segments Covered in XYZResearch Market
minor infections
complex surgery
immuno-suppressive treatments
Others

For any other requirements, please feel free to contact us and we will provide you customized report.